Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial

E. Capelletto; M.R. Migliorino; A. Morabito; R. Chiari; F. Grossi; M. Tiseo; F.D. Costanzo; A. Delmonte; G. Romano; D. Galetta; V. Scotti; V. Gregorc; S. Pisconti; G.L. Ceresoli; A.D. Conte; L. Ciuffreda; I. Colantonio; E. Bria; S. Ricciardi; A. Manzo; G. Metro; A.M. Morelli; R. Critelli; M.V. Pacchiana; I. Stura; G. Migliaretti; S. Novello

doi:10.1016/j.lungcan.2019.06.028

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial

E. Capelletto, M.R. Migliorino, A. Morabito, R. Chiari, F. Grossi, M. Tiseo, F.D. Costanzo, A. Delmonte, G. Romano, D. Galetta, V. Scotti, V. Gregorc, S. Pisconti, G.L. Ceresoli, A.D. Conte, L. Ciuffreda, I. Colantonio, E. Bria, S. Ricciardi, A. ManzoG. Metro, A.M. Morelli, R. Critelli, M.V. Pacchiana, I. Stura, G. Migliaretti, S. Novello

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	210-217
Number of pages	8
Journal	Lung Cancer
Volume	134
DOIs	https://doi.org/10.1016/j.lungcan.2019.06.028
Publication status	Published - 2019

Keywords

Docetaxel
Nintedanib
Non-small cell lung cancer
Quality of life
Toxicity
alanine aminotransferase
aspartate aminotransferase
docetaxel
gamma glutamyltransferase
nintedanib
adult
afebrile neutropenia
aged
allergic reaction
alopecia
anemia
arterial thromboembolism
Article
cancer control
cancer patient
cancer recurrence
cancer staging
clinical feature
cohort analysis
controlled clinical trial
controlled study
coughing
diarrhea
digestive system perforation
drug dose reduction
drug efficacy
drug safety
drug tolerability
drug withdrawal
dyspnea
fatigue
female
fever
follow up
human
hypersensitivity
hypertension
hypertransaminasemia
leukocyte count
leukopenia
maintenance chemotherapy
major clinical study
male
multiple cycle treatment
nail disease
nausea
neutropenia
non small cell lung cancer
open study
oral mucositis
outcome assessment
overall survival
pain
paresthesia
phase 2 clinical trial
priority journal
progression free survival
quality of life
respiratory tract hemorrhage
side effect
skin toxicity
survival time
thrombocytopenia
vein thrombosis
vomiting

Cite this

Capelletto, E., Migliorino, M. R., Morabito, A., Chiari, R., Grossi, F., Tiseo, M., Costanzo, F. D., Delmonte, A., Romano, G., Galetta, D., Scotti, V., Gregorc, V., Pisconti, S., Ceresoli, G. L., Conte, A. D., Ciuffreda, L., Colantonio, I., Bria, E., Ricciardi, S., ... Novello, S. (2019). Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer, 134, 210-217. https://doi.org/10.1016/j.lungcan.2019.06.028

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. / Capelletto, E.; Migliorino, M.R.; Morabito, A.; Chiari, R.; Grossi, F.; Tiseo, M.; Costanzo, F.D.; Delmonte, A.; Romano, G.; Galetta, D.; Scotti, V.; Gregorc, V.; Pisconti, S.; Ceresoli, G.L.; Conte, A.D.; Ciuffreda, L.; Colantonio, I.; Bria, E.; Ricciardi, S.; Manzo, A.; Metro, G.; Morelli, A.M.; Critelli, R.; Pacchiana, M.V.; Stura, I.; Migliaretti, G.; Novello, S.

In: Lung Cancer, Vol. 134, 2019, p. 210-217.

Research output: Contribution to journal › Article

Capelletto, E, Migliorino, MR, Morabito, A, Chiari, R, Grossi, F, Tiseo, M, Costanzo, FD , Delmonte, A , Romano, G , Galetta, D , Scotti, V , Gregorc, V, Pisconti, S, Ceresoli, GL, Conte, AD, Ciuffreda, L, Colantonio, I, Bria, E, Ricciardi, S, Manzo, A, Metro, G, Morelli, AM, Critelli, R, Pacchiana, MV, Stura, I, Migliaretti, G & Novello, S 2019, 'Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial', Lung Cancer, vol. 134, pp. 210-217. https://doi.org/10.1016/j.lungcan.2019.06.028

Capelletto, E. ; Migliorino, M.R. ; Morabito, A. ; Chiari, R. ; Grossi, F. ; Tiseo, M. ; Costanzo, F.D. ; Delmonte, A. ; Romano, G. ; Galetta, D. ; Scotti, V. ; Gregorc, V. ; Pisconti, S. ; Ceresoli, G.L. ; Conte, A.D. ; Ciuffreda, L. ; Colantonio, I. ; Bria, E. ; Ricciardi, S. ; Manzo, A. ; Metro, G. ; Morelli, A.M. ; Critelli, R. ; Pacchiana, M.V. ; Stura, I. ; Migliaretti, G. ; Novello, S. / Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. In: Lung Cancer. 2019 ; Vol. 134. pp. 210-217.

@article{d312ed2cb8224fed918ac5c0cf39e5d9,

title = "Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial",

keywords = "Docetaxel, Nintedanib, Non-small cell lung cancer, Quality of life, Toxicity, alanine aminotransferase, aspartate aminotransferase, docetaxel, gamma glutamyltransferase, nintedanib, adult, afebrile neutropenia, aged, allergic reaction, alopecia, anemia, arterial thromboembolism, Article, cancer control, cancer patient, cancer recurrence, cancer staging, clinical feature, cohort analysis, controlled clinical trial, controlled study, coughing, diarrhea, digestive system perforation, drug dose reduction, drug efficacy, drug safety, drug tolerability, drug withdrawal, dyspnea, fatigue, female, fever, follow up, human, hypersensitivity, hypertension, hypertransaminasemia, leukocyte count, leukopenia, maintenance chemotherapy, major clinical study, male, multiple cycle treatment, nail disease, nausea, neutropenia, non small cell lung cancer, open study, oral mucositis, outcome assessment, overall survival, pain, paresthesia, phase 2 clinical trial, priority journal, progression free survival, quality of life, respiratory tract hemorrhage, side effect, skin toxicity, survival time, thrombocytopenia, vein thrombosis, vomiting",

author = "E. Capelletto and M.R. Migliorino and A. Morabito and R. Chiari and F. Grossi and M. Tiseo and F.D. Costanzo and A. Delmonte and G. Romano and D. Galetta and V. Scotti and V. Gregorc and S. Pisconti and G.L. Ceresoli and A.D. Conte and L. Ciuffreda and I. Colantonio and E. Bria and S. Ricciardi and A. Manzo and G. Metro and A.M. Morelli and R. Critelli and M.V. Pacchiana and I. Stura and G. Migliaretti and S. Novello",

note = "Export Date: 30 January 2020 CODEN: LUCAE Correspondence Address: Capelletto, E.; Department of Oncology, University of Turin, Regione Gonzole 10, Italy; email: enrica.capelletto@gmail.com",

year = "2019",

doi = "10.1016/j.lungcan.2019.06.028",

language = "English",

volume = "134",

pages = "210--217",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial

AU - Capelletto, E.

AU - Migliorino, M.R.

AU - Morabito, A.

AU - Chiari, R.

AU - Grossi, F.

AU - Tiseo, M.

AU - Costanzo, F.D.

AU - Delmonte, A.

AU - Romano, G.

AU - Galetta, D.

AU - Scotti, V.

AU - Gregorc, V.

AU - Pisconti, S.

AU - Ceresoli, G.L.

AU - Conte, A.D.

AU - Ciuffreda, L.

AU - Colantonio, I.

AU - Bria, E.

AU - Ricciardi, S.

AU - Manzo, A.

AU - Metro, G.

AU - Morelli, A.M.

AU - Critelli, R.

AU - Pacchiana, M.V.

AU - Stura, I.

AU - Migliaretti, G.

AU - Novello, S.

N1 - Export Date: 30 January 2020 CODEN: LUCAE Correspondence Address: Capelletto, E.; Department of Oncology, University of Turin, Regione Gonzole 10, Italy; email: enrica.capelletto@gmail.com

PY - 2019

Y1 - 2019

KW - Docetaxel

KW - Nintedanib

KW - Non-small cell lung cancer

KW - Quality of life

KW - Toxicity

KW - alanine aminotransferase

KW - aspartate aminotransferase

KW - docetaxel

KW - gamma glutamyltransferase

KW - nintedanib

KW - adult

KW - afebrile neutropenia

KW - aged

KW - allergic reaction

KW - alopecia

KW - anemia

KW - arterial thromboembolism

KW - Article

KW - cancer control

KW - cancer patient

KW - cancer recurrence

KW - cancer staging

KW - clinical feature

KW - cohort analysis

KW - controlled clinical trial

KW - controlled study

KW - coughing

KW - diarrhea

KW - digestive system perforation

KW - drug dose reduction

KW - drug efficacy

KW - drug safety

KW - drug tolerability

KW - drug withdrawal

KW - dyspnea

KW - fatigue

KW - female

KW - fever

KW - follow up

KW - human

KW - hypersensitivity

KW - hypertension

KW - hypertransaminasemia

KW - leukocyte count

KW - leukopenia

KW - maintenance chemotherapy

KW - major clinical study

KW - male

KW - multiple cycle treatment

KW - nail disease

KW - nausea

KW - neutropenia

KW - non small cell lung cancer

KW - open study

KW - oral mucositis

KW - outcome assessment

KW - overall survival

KW - pain

KW - paresthesia

KW - phase 2 clinical trial

KW - priority journal

KW - progression free survival

KW - quality of life

KW - respiratory tract hemorrhage

KW - side effect

KW - skin toxicity

KW - survival time

KW - thrombocytopenia

KW - vein thrombosis

KW - vomiting

U2 - 10.1016/j.lungcan.2019.06.028

DO - 10.1016/j.lungcan.2019.06.028

M3 - Article

VL - 134

SP - 210

EP - 217

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -

Access to Document

10.1016/j.lungcan.2019.06.028

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068129572&doi=10.1016%2fj.lungcan.2019.06.028&partnerID=40&md5=cc3ecf5d442a3e0eaa801bcd39f5efd6

Projects

MAGGIORE - EMERGENZA-URGENZA NELLE GRANDI CRONICITA'

Project: Other project

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial

Keywords

Cite this

Access to Document

Related content

Projects

MAGGIORE - EMERGENZA-URGENZA NELLE GRANDI CRONICITA'